Literature DB >> 19561791

Prescribing trends with daptomycin (cubicin) for the treatment of gram-positive infections.

Noreen H Chan Tompkins1, Stephen J Harnicar.   

Abstract

The injectable agent daptomycin, when prescribed according to approved guidelines, can be a welcome option for treating some multiresistant, gram-positive infections that have become increasingly prevalent.

Entities:  

Year:  2008        PMID： 19561791      PMCID： PMC2683600     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  17 in total

1.  An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus.

Authors:  Jean B Patel; Laura A Jevitt; Jeffery Hageman; L Clifford McDonald; Fred C Tenover
Journal:  Clin Infect Dis       Date:  2006-06-01       Impact factor: 9.079

2.  Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy.

Authors:  Paul G Mariani; Helio S Sader; Ronald N Jones
Journal:  J Antimicrob Chemother       Date:  2006-08       Impact factor: 5.790

3.  Diminished susceptibility to daptomycin accompanied by clinical failure in a patient with methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  David Hirschwerk; Christine C Ginocchio; Maureen Bythrow; Susan Condon
Journal:  Infect Control Hosp Epidemiol       Date:  2006-02-23       Impact factor: 3.254

4.  Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.

Authors:  Vance G Fowler; Helen W Boucher; G Ralph Corey; Elias Abrutyn; Adolf W Karchmer; Mark E Rupp; Donald P Levine; Henry F Chambers; Francis P Tally; Gloria A Vigliani; Christopher H Cabell; Arthur Stanley Link; Ignace DeMeyer; Scott G Filler; Marcus Zervos; Paul Cook; Jeffrey Parsonnet; Jack M Bernstein; Connie Savor Price; Graeme N Forrest; Gerd Fätkenheuer; Marcelo Gareca; Susan J Rehm; Hans Reinhardt Brodt; Alan Tice; Sara E Cosgrove
Journal:  N Engl J Med       Date:  2006-08-17       Impact factor: 91.245

5.  Rhabdomyolysis during therapy with daptomycin.

Authors:  Stella Papadopoulos; Amanda M Ball; Susanne E Liewer; Craig A Martin; P Shane Winstead; Brian S Murphy
Journal:  Clin Infect Dis       Date:  2006-05-10       Impact factor: 9.079

6.  Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers.

Authors:  Mark Benvenuto; David P Benziger; Sara Yankelev; Gloria Vigliani
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

Review 7.  Daptomycin.

Authors:  Kerry L Tedesco; Michael J Rybak
Journal:  Pharmacotherapy       Date:  2004-01       Impact factor: 4.705

8.  Clinical experience with daptomycin for the treatment of patients with osteomyelitis.

Authors:  Kenneth C Lamp; Lawrence V Friedrich; Luke Mendez-Vigo; Rene Russo
Journal:  Am J Med       Date:  2007-10       Impact factor: 4.965

9.  Daptomycin in the treatment of patients with infective endocarditis: experience from a registry.

Authors:  Donald P Levine; Kenneth C Lamp
Journal:  Am J Med       Date:  2007-10       Impact factor: 4.965

10.  Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.

Authors:  Manjunath P Pai; Jeffrey P Norenberg; Tamara Anderson; Diane W Goade; Keith A Rodvold; Robert A Telepak; Renee-Claude Mercier
Journal:  Antimicrob Agents Chemother       Date:  2007-06-04       Impact factor: 5.191
View more
  5 in total

Review 1.  Therapeutic cyclic lipopeptides mining from microbes: latest strides and hurdles.

Authors:  Seema Patel; Shadab Ahmed; J Satya Eswari
Journal:  World J Microbiol Biotechnol       Date:  2015-06-04       Impact factor: 3.312

Review 2.  Once-Daily Treatments for Methicillin-Susceptible Staphylococcus aureus Bacteremia: Are They Good Enough?

Authors:  Sylvain A Lother; Natasha Press
Journal:  Curr Infect Dis Rep       Date:  2017-09-23       Impact factor: 3.725

3.  Effect of ester to amide or N-methylamide substitution on bacterial membrane depolarization and antibacterial activity of novel cyclic lipopeptides.

Authors:  Nina Bionda; Renee M Fleeman; Lindsey N Shaw; Predrag Cudic
Journal:  ChemMedChem       Date:  2013-06-18       Impact factor: 3.466

4.  Development of High-Level Daptomycin Resistance in Abiotrophia and Granulicatella Species Isolates from Patients with Infective Endocarditis.

Authors:  María A Cañas; Adrian Téllez; Cristina García de la Mària; Anders Dahl; Javier García-González; Marta Hernández-Meneses; Manel Almela; Juan Ambrosioni; Carlos Falces; Eduard Quintana; Barbara Vidal; Andres Perissinotti; José M Tolosana; Elena Sandoval; Juan M Pericàs; Asunción Moreno; José M Miró
Journal:  Antimicrob Agents Chemother       Date:  2021-07-12       Impact factor: 5.191

5.  Chemoenzymatic synthesis of daptomycin analogs active against daptomycin-resistant strains.

Authors:  Erin M Scull; Chandrasekhar Bandari; Bryce P Johnson; Eric D Gardner; Marco Tonelli; Jianlan You; Robert H Cichewicz; Shanteri Singh
Journal:  Appl Microbiol Biotechnol       Date:  2020-07-28       Impact factor: 5.560
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.